You are here

  • Home
  • Archive
  • Volume 69, Issue 2
  • Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

Article Text

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study
  1. S W Syversen1,2,
  2. G L Goll1,
  3. D van der Heijde1,3,
  4. R Landewé4,
  5. B A Lie5,
  6. S Ødegård1,
  7. T Uhlig1,
  8. P I Gaarder6,
  9. T K Kvien1
  1. 1
    Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
  2. 2
    Faculty of Medicine, University of Oslo, Oslo, Norway
  3. 3
    Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
  4. 4
    Department of Rheumatology, University Hospital Maastricht, Maastricht, The Netherlands
  5. 5
    Institute of Immunology, Rikshospitalet University hospital, Oslo, Norway
  6. 6
    Department of Immunology and Transfusion Medicine, University Hospital Ullevål, Oslo, Norway
  1. Correspondence to S W Syversen, Department of Rheumatology, Diakonhjemmet Hospital, PB 23 Vindern, N-0319 Oslo, Norway; s.w.syversen{at}medisin.uio.no

Abstract

Objectives: Anti-citrullinated peptide antibodies (ACPAs) are established as useful predictors of radiographic progression in rheumatoid arthritis (RA). The main objective of this study was to test the prognostic capacity of the recently developed test for anti-mutated citrullinated vimentin (anti-MCV).

Methods: A cohort of 238 patients with RA was followed longitudinally for 10 years; 125 patients with complete x ray sets were included in the main analyses. Radiographs were scored according to the van der Heijde modified Sharp score (SHS). Patients were analysed for anti-MCV and anti-cyclic citrullinated peptide (CCP), and were genotyped for human leukocyte antigen (HLA)-DRB1 “shared epitope” (SE) and protein tyrosine phosphatase, non-receptor type 22 (PTPN22) 1858T.

Results: Anti-MCV and anti-CCP were strongly associated with regard to status and level. Both antibodies were associated with SE, but only anti-MCV was significantly associated with PTPN22 1858T. A positive anti-MCV test increased the odds of radiographic progression by 7.3 (95% confidence interval (CI) 3.2 to 16.5) compared to 5.7 (95% CI 2.6 to 12.5) for a positive anti-CCP. Presence of MCV antibodies gave an average increase in the total SHS of 30 U compared to an average increase of 25 U for the presence of CCP antibodies. Anti-MCVs were more strongly associated to progression in erosions than joint space narrowing. Associations remained after adjustment for other predictors of radiographic progression. The odds of progression increased with increasing anti-MCV level.

Conclusions: Presence of anti-MCV predicted joint damage, and the strength of this prediction was at least as strong as for anti-CCP. Antibody status showed a stronger association to bone than to cartilage destruction. This study also indicates that higher anti-MCV levels add prognostic information compared to their mere presence or absence.

https://doi.org/10.1136/ard.2009.113092

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • ▸ Additional data (supplementary table 1) are published online only at http://ard.bmj.com/content/vol69/issue2

    • Funding This study has been financed with grants from the Eastern Norway Regional Health Authority, the Norwegian Foundation for Health and Rehabilitation and the Norwegian Women Public Health Association.

    • Competing interests Hans Bijlsma was the Handling Editor for this article.

    • Ethics approval The regional ethics committee granted approval.

    • Provenance and Peer review Not commissioned; externally peer reviewed.